Humacyte, Inc. (HUMA) News
Filter HUMA News Items
HUMA News Results
Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
---|---|---|---|---|---|---|---|---|---|
Loading, please wait... |
HUMA News Highlights
- HUMA's 30 day story count now stands at 2.
- Over the past 18 days, the trend for HUMA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about HUMA are DEC and NOV.
Latest HUMA News From Around the Web
Below are the latest news stories about HUMACYTE INC that investors may wish to consider to help them evaluate HUMA as an investment opportunity.
Humacyte Submits Biologics License Application (BLA) to U.S. FDA Seeking Approval of Human Acellular Vessel™ (HAV™) for the Treatment of Vascular Trauma– BLA supported by results from Phase 2/3 clinical trial and outcomes of real-world use of the HAV under a humanitarian aid program to treat wartime trauma injuries in Ukraine – – The HAV had higher rates of patency, and lower rates of amputation and infection, compared to historic synthetic graft benchmarks – DURHAM, N.C., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissu |
Humacyte to Present at the Piper Sandler 35th Annual Healthcare ConferenceDURHAM, N.C., Nov. 24, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Founder, President, and Chief Executive Officer, and Dale Sander, Chief Financial Officer, will present at the Piper Sandler 35th Annual Healthcare Conference, in New York, NY on November 30, 2023. Management will also be available for one |
Humacyte Announces Two Presentations at the VEITHsymposium® of Positive Clinical Results of the Human Acellular Vessel™ (HAV™) in the Treatment of Vascular Trauma– Presentations included results from Phase 2/3 clinical trial and outcomes of real-world use of the HAV under a humanitarian aid program to treat wartime injuries in Ukraine – – Results showed the HAV had higher rates of patency, and lower rates of amputation and infection, compared to historic synthetic graft benchmarks – – BLA for an indication in vascular trauma planned to be filed with the FDA during the current quarter – DURHAM, N.C., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasda |
Sidoti Events, LLC’s Virtual November Micro-Cap ConferenceNEW YORK, NY / ACCESSWIRE / November 14, 2023 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day November Micro-Cap Conference taking place Wednesday and Thursday, November ... |
Humacyte Third Quarter 2023 Financial Results and Business Update– Positive top line results from the V005 Phase 2/3 trial of the Human Acellular Vessel™ (HAV™) in vascular trauma repair – – BLA for an indication in vascular trauma planned to be filed with the FDA during the current quarter – - Conference call and live webcast at 4:30 p.m. ET today - DURHAM, N.C., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, t |
Humacyte to Present Third Quarter Financial Results and Provide Corporate Update on November 9, 2023DURHAM, N.C., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results for the third quarter ended September 30, 2023, on Thursday, November 9, 2023. Management will host a webcast and conference call at 4:30 p.m. ET to provide a corporate and financial update. Title:Humacyte Third Quarter 2023 Earnings Conference CallDate: |
Humacyte Publishes Preclinical Results Showing Human Acellular Vessel™ (HAV™) Patency as Modified Blalock–Taussig–Thomas Shunt in Juvenile Primate Model-Outcomes exhibit potential of HAV for palliative treatment of congenital heart disease-DURHAM, N.C., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced publication of a preclinical study showing the potential for its investigational small-diameter Human Acellular Vessel™ (HAV™) to treat Tetralogy of Fallot, a heart condition that affects one |
Several Insiders Invested In Humacyte Flagging Positive NewsWhen a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase... |
'Politicians have too much power': Sen. Tommy Tuberville recently disclosed $250K in agriculture futures — all while he's been influencing farming industry policiesAnd that's not the senator's only recent profitable trade that's drawing attention. |
Humacyte to Present at the Cantor Global Healthcare ConferenceDURHAM, N.C., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Founder, President, and Chief Executive Officer, and Dale Sander, Chief Financial Officer, will present at the Cantor Global Healthcare Conference, in New York, NY on September 28, 2023. Management will also be available for one-on-one me |